| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/17/2003 | WO2003030875A1 Over-coated chewing gum formulations including tableted center |
| 04/17/2003 | WO2003030867A2 Method for preparing an interactive compound of an anilide derivative with a porous support by supercritical fluid |
| 04/17/2003 | WO2003030833A2 Angiopoietin-2 specific binding agents |
| 04/17/2003 | WO2003030829A2 Liposome-encapsulated insulin formulations |
| 04/17/2003 | WO2003030823A2 Combinations for the treatment of immunoinflammatory disorders |
| 04/17/2003 | WO2003030616A2 21132, a human g-protein coupled receptor family member and uses therefor |
| 04/17/2003 | WO2003030612A2 Methods for modulating activity of the fxr nuclear receptor |
| 04/17/2003 | WO2003017927A3 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor |
| 04/17/2003 | WO2003013585A8 Mifaxin agonists and antagonists for use in the treatment of metabolic |
| 04/17/2003 | WO2003006004A3 Pharmaceutical compositions for oral use, containing, in combination, metformin and glicazide, a sulphonyl urea |
| 04/17/2003 | WO2002089770A3 Topical lamellar double membrane structure composition containing n-acyl-ethanolamine and/or a quaternary ammonium salt and/or adenosylmethionine |
| 04/17/2003 | WO2002085930A3 Immunomodulating agents from parasitic worms and method for isolation thereof |
| 04/17/2003 | WO2002079221A3 Sapogenin derivatives, their synthesis and use |
| 04/17/2003 | WO2002070706A3 Interleukin-8 homologous polypeptides and therapeutic uses thereof |
| 04/17/2003 | WO2002058707A3 Method of treatment of type i diabetes with vitamin d compounds |
| 04/17/2003 | WO2002050289A9 Methods for the production of multimeric proteins, and related compositions |
| 04/17/2003 | WO2002050284A3 Oxidoreductases |
| 04/17/2003 | WO2002029036A3 Lipid metabolism enzymes |
| 04/17/2003 | WO2002024891A3 B7-like molecules and uses thereof |
| 04/17/2003 | WO2002020619A9 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 04/17/2003 | WO2002018445A3 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 04/17/2003 | WO2001089494A8 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
| 04/17/2003 | WO2001078709A3 Treatment of neurodegenerative disease |
| 04/17/2003 | WO2001076573A3 Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups |
| 04/17/2003 | WO2001072752A3 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS |
| 04/17/2003 | WO1999064401A3 Imidazolyl derivatives and their use as somatostatin receptor ligands |
| 04/17/2003 | US20030073849 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors |
| 04/17/2003 | US20030073846 Aminoalcohol derivatives |
| 04/17/2003 | US20030073819 PGC-1, a novel brown fat PPARgamma coactivator |
| 04/17/2003 | US20030073733 Pharmaceutically active compounds and methods of use |
| 04/17/2003 | US20030073729 Medicaments for diabetic complication and neuropathy, and uses thereof |
| 04/17/2003 | US20030073723 Antiinflammatory agents; rheumatic diseases; antiallergens |
| 04/17/2003 | US20030073719 Chiral salt resolution |
| 04/17/2003 | US20030073718 Enzyme inhibitors; cardiovascular disorders; antiinflammatory agents; autoimmune disease |
| 04/17/2003 | US20030073712 Antiinflamamtory agents; antiischemic agents |
| 04/17/2003 | US20030073710 Compounds useful for treatment or prevention of disease mediated by alpha-2B-adrenoceptor |
| 04/17/2003 | US20030073705 Method of treatment |
| 04/17/2003 | US20030073704 Analgesics; antidiabetic agents; antiinflamamtory agents |
| 04/17/2003 | US20030073700 Central nervous system disorders; Parkinson's disease, Huntington's disease; psycological disorders |
| 04/17/2003 | US20030073685 Nitric oxide synthase inhibitor; antiinflammatory agents |
| 04/17/2003 | US20030073684 Respiratory system disorders; cardiovascular disorders; hemorrhage therapy |
| 04/17/2003 | US20030073669 N-heterocyclic derivatives as NOS inhibitors |
| 04/17/2003 | US20030073631 Improved pharmacological activities, pharmacokinetics and physical properties; modified with 1-acyl-glycerol derivative |
| 04/17/2003 | US20030073627 Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases |
| 04/17/2003 | US20030073621 Antidiabetic agents; isolated nucleic acid; genetic engineering |
| 04/17/2003 | US20030073167 DNA encoding SNORF36 receptors |
| 04/17/2003 | US20030072824 Having anti-oxidant, gastric mucosa injury inhibiting, aldose reductase inhibiting, blood glucose level elevation inhibiting action, platelet agglutination accelerating action, alcohol absorption inhibition, anti-inflammation properties |
| 04/17/2003 | US20030072822 Methods for treating disorders using plant extracts |
| 04/17/2003 | US20030072804 Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body |
| 04/17/2003 | US20030072785 Mixtures for stimulating glucose up-take |
| 04/17/2003 | US20030072754 CD154 blockade therapy for pancreatic islet tissue transplantation |
| 04/17/2003 | US20030072737 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 04/17/2003 | CA2464662A1 Modulation of the expression of genes dependent on stat-1 |
| 04/17/2003 | CA2463364A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors |
| 04/17/2003 | CA2463339A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound |
| 04/17/2003 | CA2462950A1 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors |
| 04/17/2003 | CA2462881A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process |
| 04/17/2003 | CA2462862A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists |
| 04/17/2003 | CA2462301A1 Para-amino benzoic acids as integrin antagonists |
| 04/17/2003 | CA2462185A1 Methods for modulating activity of the fxr nuclear receptor |
| 04/17/2003 | CA2461435A1 Angiopoietin-2 specific binding agents |
| 04/17/2003 | CA2461369A1 Arylsulphonyl-substituted tetrahydro-and-hexahydro-carbazoles as 5-ht-6 receptor ligands |
| 04/17/2003 | CA2461048A1 Liposome-encapsulated insulin formulations |
| 04/17/2003 | CA2460476A1 Protein modification and maintenance molecules |
| 04/16/2003 | EP1302542A1 Novel physiologically active peptide and use thereof |
| 04/16/2003 | EP1302476A1 Reduced fk228 and use thereof |
| 04/16/2003 | EP1302201A1 Pharmaceutical composition improved in peroral absorbability |
| 04/16/2003 | EP1302115A1 Use of cystathionine |
| 04/16/2003 | EP1302114A2 Mixtures for stimulating glucose up-take |
| 04/16/2003 | EP1301598A2 Cell cycle proteins and mitosis-associated molecules |
| 04/16/2003 | EP1301595A2 G-protein coupled receptors |
| 04/16/2003 | EP1301535A2 G-protein coupled receptors |
| 04/16/2003 | EP1301524A1 B7-like polynucleotides, polypeptides, and antibodies |
| 04/16/2003 | EP1301522A1 Novel compounds and methods |
| 04/16/2003 | EP1301516A1 Modulators of protein tyrosine phosphatases (ptpases) |
| 04/16/2003 | EP1301514A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| 04/16/2003 | EP1301511A2 IMIDAZO 1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| 04/16/2003 | EP1301507A2 Mannich base prodrugs of 3 - (pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases |
| 04/16/2003 | EP1301501A1 Tocotrienolquinone cyclisation product with an anti-hypercholesterol effect |
| 04/16/2003 | EP1301497A1 Colchinol derivatives as vascular damaging agents |
| 04/16/2003 | EP1301495A2 Inhibitors of copper-containing amine oxidases |
| 04/16/2003 | EP1301490A2 5-substituted 2-aryl-4-pyrimidinones |
| 04/16/2003 | EP1301482A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 04/16/2003 | EP1301480A1 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| 04/16/2003 | EP1301479A2 STABILIZED 1$g(a)-HYDROXY VITAMIN D |
| 04/16/2003 | EP1301476A1 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation |
| 04/16/2003 | EP1301475A1 Aryl sulfonamides as serotonin antagonist for the treatment of obesity |
| 04/16/2003 | EP1301474A2 Tyrosine derivatives as phosphatase inhibitors |
| 04/16/2003 | EP1301464A1 Biphenylcarboxylic acid amides, production thereof and use thereof as medicaments |
| 04/16/2003 | EP1301213A2 Multi-component biological transport systems |
| 04/16/2003 | EP1301206A1 Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| 04/16/2003 | EP1301201A1 Treatment of glycogen storage disease type ii |
| 04/16/2003 | EP1301200A2 Peptide pharmaceutical formulations |
| 04/16/2003 | EP1301198A2 Fusion protein for inhibition of lipoprotein secretion |
| 04/16/2003 | EP1301187A2 Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv |
| 04/16/2003 | EP1301181A2 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds |
| 04/16/2003 | EP1181047B1 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
| 04/16/2003 | EP1163224B1 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance |
| 04/16/2003 | EP1123093B1 Ubiquinone-containing composition suitable for promoting enhanced intramitochondrial transportation of ubiquinones and methods of using same |
| 04/16/2003 | EP1090027B1 Novel 17-halogenated 19-nor steroids, method and intermediates for preparing same, use as medicines and pharmaceutical compositions containing same |